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Clearance of a drug during hemodialysis is affected by drug
specific, membrane specific and dialysis specific factors [I, 21.
Drug specific properties determining dialysability include its
volume of distribution (Vd), protein binding and molecular
weight. Dialyzer membrane specific factors include surface
area, permeability and adherence of the drug to the membrane.
Finally, blood flow and dialysate flow also influence drug
clearance.
Vancomycin is commonly used in patients for the treatment
of gram + infections. More than 90% of the drug is excreted by
the kidneys; however, in the presence of renal failure significant
dosage adjustments are required. The half life of vancomycin is
quite prolonged in ESRD (200 hours) as compared to those with
normal renal function (6 to 8 hours) [3—9]. Typically, vancomy-
cm is not appreciably removed by the cuprophane or cellulose
acetate membranes used in conventional hemodialysis. How-
ever, with the introduction of the newer, more permeable
membranes, such as the polysulfone dialyzers, the pharmaco-
kinetics of vancomycin removal during hemodialysis may be
increased since vancomycin has a small Vd (0.47 to 0.84 liter!
kg), minimal protein binding [3, 5, 9] and a relatively low
molecular weight (1500 daltons) [31. The purpose of the present
study was therefore, to determine whether polysulfone mem-
branes increased the clearance of vancomycin.
Methods
Six male patients on chronic hemodialysis were studied in a
paired fashion with each patient being studied on each dialyzer
membrane and, therefore, serving as his own control. All
patients were dialyzed on a Fresenius A 2008C hemodialysis
machine. Unless otherwise stated, the dialysis prescription was
held constant for all patients with respect to a blood flow rate of
250 mI/mm with a bicarbonate dialysate (ph 7.2) flow rate of 500
mI/mm. Vancomycin clearance was determined for the Trave-
nol 12.11 cuprophane (surface area 0.8 m2) and the Fresenius
polysulfone F-40, F-60, F-80 dialyzers with surface areas of
0.65, 1.2 and 1.9 m2, respectively.
Analytical procedures
Plasma vancomycin levels were determined using the Abbott
TDx TM drug assay system as we have previously reported [4].
Initial plasma vancomycin levels were not statistically different
when cuprophane or polysulfone dialyzers were studied (20.0
5.5 vs. 18.3 4.3 gIml). Plasma vancomycin clearances were
calculated using simultaneous arterial (pre-dialyzer) and venous
(post-dialyzers) extraction values based on total plasma vanco-
mycin levels. At least five clearance determinations (hourly)
throughout the four-hour dialysis session were used to calculate
vancomycin clearance for an individual patient. The formula to
calculate plasma vancomycin clearance was QB (100%-hemato-
crit %) (A-V/A), where A and V refer to arterial and venous
plasma vancomycin concentrations, respectively. Ultrafiltra-
tion rates were not included in this calculation. The intradialytic
half-life of vancomycin (t 1/2) was calculated using standard,
first-order kinetic equations based on decay curves with at least
five arterial serum vancomycin levels collected over the four
hour dialysis. Data, expressed as the mean standard devia-
tion, were analyzed using the Student's t-test unless otherwise
noted. P values less than <0.05 were considered significant and
were reported as either <0.05 or <0.01.
Results
Figure IA shows the change in plasma vancomycin concen-
tration in each patient studied during a four hour hemodialysis
using the Travenol model 12.11. The cuprophane dialyzer
resulted in a minimal decrease in plasma vancomycin concen-
tration (20.2 5.7 vs. 18.8 5.0) during four hours of
hemodialysis. However, the Fresenius polysulfone F-80
dialyzer affected a marked reduction in plasma vancomycin
concentration in each patient studied during a four hour dialysis
(15.7 3.9 vs. 8.0 1.9, P < 0.01), as shown in Figure lB.
The disappearance of plasma vancomycin during hemodialy-
sis with different dialyzers was then quantitated by calculating
the percent removed, the intradialytic t 1/2, and the clearance of
vancomycin. These data are shown in Table I. Vancomycin
removal increased from 6.9% using the cuprophane dialyzer to
49,5% using the polysulfone F-80 dialyzer. Within the polysul-
fone series there was a linear relationship between surface area
of the dialyzer and the amount of vancomycin removed (r =
0.94, N = 10, P < 0.01). Using the cuprophane dialyzer the
intradialytic t 1/2 of vancomycin was 35.1 11.2 hours, while
all the polysulfone dialyzers showed a markedly reduced intra-
dialytic t 1/2. For the polysulfone dialyzers there was an inverse
relationship between the surface area of the dialyzer and the
intradialytic t 1/2 of vancomycin (r = 0.74, P < 0.05).
Figure 2. shows the effect of a surface area upon plasma
vancomycin clearance during hemodialysis with the polysul-
fone membrane dialyzer series. The clearance of vancomycin
was markedly enhanced with increased dialyzer surface area (r
= 0.95, P < 0.01). The clearance of vancomycin using the F-40
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Fig. 1. The change in plasma vancomycin
levels during hemodialysis with the Tra venal
/2./I cuprophane (A) andFresenius
polysulfone F'-80 dialyzers (B). Individual0 1 2 3
symbols represent the same patient dialyzed
on the two different membranes.
Table 1. Effect of different dialyzers on the clearance and intradialytic t 1/2 of plasma vancomycin
Vancomycin
removalSurface area
Membrane m2 %
Vancomycin
clearance
mI/inin"
Intradialytic t 1/2
hoursc
Cuprophane 0.80 35.1 11.2
Polysulfone F-40 0.65 11.8 5.6
Polysulfone F-60 1.20 6.7 1.0
Polysulfone F-80 1.90 4.5 0.1
U Vancomycin removal was calculated using arterial pre-dialysis and post-dialysis plasma levels immediately prior to and following a 4 hour
dialysis session. QB and QD were 250 and 500 mI/mm, respectively.
'The data represent the mean so. N = 4 for the cuprophane and F-80 and 3 for the F-40 and F-60 dialyzers.
C The mntradialytic t 1/2 of vancomycin was determined during the entire 4 hours of hemodialysis and based on 5 arterial levels.
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individual data points are shown for three patients each dialyzed using
an F-40, F-60 and F-80 Fresenius polysulfone dialyzer. Linear regres-
sion revealed a correlation of 0.95, P < 0.01.
(0.65 m2) was 44.7 6.7 mI/mm, while that of the F-SO (1.9 m2)
increased to 85.2 7.0 mI/mm (Table I). Both these clearance
values are significantly greater (P < 0.01) than that obtained
with the Travenol cuprophane dialyzer (9.6 2.9 mI/mm).
Finally, to determine the effect of QB and plasma flow rate
(Q) on plasma vancomycin clearance with the F-80 dialyzer,
QB was varied from 200 to 400 mI/mm. Vancomycin clearance
(Fig. 3) increased linearly over the range of QB studied from
83.7 5.5 to 104.9 8.8 mI/mm. A highly significant correla-
tion was also noted between Q and vancomycin clçarance (P <
0.01).
Discussion
Vancomycin is an effective and widely used antibiotic for the
treatment of gram positive infections in dialysis patients. This is
in part due to its ease of administration (I g i.v. every 7 to 10
days). Vancomycin, however, is somewhat unique in that it has
a small Vd and has a relatively small molecular weight allowing
its unhindered filtration across the glomerulus. Its clearance
during hemodialysis, therefore, is primarily a function of the
permeability of the dialysis membrane and the extent of its
binding to serum proteins. The protein binding of vancomycin
has been reported in Iwo studies (9, II] and has ranged between
10 and 55 percent. Our data is suggestive of low protein binding
as the clearance of vancomycin is 61 percent of Q at a flow rate
of 130 mI/mm. This high percent clearance would be unlikely to
occur if vancomycin was highly protein bound unless it was
bound to small molecular weight proteins which are also cleared
during high flux hemodialysis. Cellulose acetate and cupro-
phane membranes, because of there limited permeability, do
not result in effective removal of vancomycin (3—9]. Polysulfone
membranes, on the other hand, have markedly improved per-
meability characteristics. The ultrafiltration coefficient of the
F-80 dialyzer is 55 mI/hr mm Hg compared with the Travenol
A
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Fig. 3. The effect of Q8 and Q,, on plasma
vanco,n vein clearance using the F-80 dialyzer.
Vancomycin clearances were determined in
three patients at QB of 200, 300 and 400 ml!
mm. (A) The effect of QB or vancomycin
clearance. Data points represent the mean I
SD of triplicate determinations in individual
patients. Linear regression revealed a
correlation of 0.99. P < 0.01. The insert
(lower right) shows data for individual
patients designated by different symbols for
each patient. (B) The effect of Q on
vancomycin clearance. Each symbol
represents the mean of three determinations in
each patient at one Q. The correlation value
of 0.91, N = 9, is highly significant P < 0.01.
12.11 which is only 3.0 mI/hr mm Hg. This results in more rapid
clearance of "middle molecules".
In the present study we demonstrate that the polysulfone
dialyzers affect the significant removal of vancomycin as com-
pared to cuprophane dialyzers. Enhanced removal was docu-
mented by the increased clearance of vancomycin, the de-
creased intradialytic t 1/2 of vancomycin as well as the
decrement in serum vancomycin levels during the hemodialysis
session. We also showed that within the polysulfone dialyzers,
increasing the surface area enhances vancomycin clearance and
decreases the intradialytic t 1/2. Finally, as QB or Qincrease so
does vancomycin clearance with the F-80 dialyzer. The rela-
tionship between vancomycin clearance and Q.instead of QB'
is probably preferable as vancomycin does not distribute into
erythrocytes. Since patient's hematocrits may vary from 15 to
50 percent expressing the data in terms of Q removes the
variability in clearance induced by widely varying hematocrit
values.
These data have important clinical implications. First, the
standard regiment of vancomycin administration every 7 to 10
days, has to be altered when the patient is dialyzed using
polysulfone dialyzers, so as to maintain therapeutic serum
levels. Secondly, the polysulfone membrane used, the QBand
the duration of dialysis will determine how much vancomycin is
required post-dialysis. For example, it seems reasonable to
administer a post-dialysis vancomycin supplement of about
50% of the usual loading dose when a patient is dialyzing on the
polysulfone F-80 dialyzer for four hours, given the intradialytic
1/2 for vancomycin is four hours.
In an attempt to provide a clinically applicable means of
estimating vancomycin removal, we examined the relationship
between a dialyzer's B1, clearance and its degree of vancomy-
cm removal. For the four dialyzers we studied there was an
excellent linear relationship between B12 clearance and vanco-
mycin removal (Fig. 4. r = 0.99, P < 0.01). Whether this
relationship holds for all dialyzers remains to be determined.
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However, recent data from Bastani et at [121, for cellulose
acetate and polyacrylonitrile dialyzers were in close agreement
with the linear regression equation generated by our data (Fig.
4, open symbols). To this relationship one can then add
equations to factor for variable Q and the duration of dialysis,
resulting in the following equation to estimate the removal of
vancomycin, where % vancomycin removal
(1Post-dialysis level <\ Pre-dialysis level /
= (0.36 Cl, — 6) [1 + (QB — 250) (0.001)] (time(hr))
= (0.09 CIB. — 1.5) (0.75 + 0.001 QB) (time (hr))
and CIB, = manufacturers reported B1, clearance
Using the percent of vancomycin removed one can then more
accurately calculate a replacement dose. These data, however,
are based on data derived using the polysulfone F40-80 dialy-
zers. Whether they hold for all dialyzers remains to be shown.
In summary, use of the highly permeable polysulfone mem-
brane necessitates supplemental vancomycin administration
following each dialysis session to maintain therapeutic vanco-
mycin plasma levels. The amount of supplementation will be
dependent upon the duration of dialysis, dialysate flow rate,
blood flow rate and polysulfone dialyzer utilized. In addition,
other drugs with relatively small Vd, minimal protein binding
and a molecular weight in the range of 1,000 to 12,000 daltons
may also require supplementation following dialysis with highly
permeable membranes.
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Fig. 4. The correlation between the percent
decrease in plasma vancomycin levels and the
B,2 clearance of individual dialyzers. Filled
symbols are from the present study and the
linear regression equation is based on those 4
data points. The open symbols represent data
on cellulose acetate (Cordis Dow 4000) and
polyacrylonitrile (Hospal 2400S AN 695)
160 dialyzers taken from Bastani et al [(2]. For alldata points QB and the time of hemodialysis
were 250 mI/mm and 4 hours, respectively.
